Logo
x

Search

Subscribe Now

infants

Genentech Presents Results of Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA at AAN2021

Genentech Presents Results of Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA at AAN2021

  • April 15, 2021
Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA

Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA

  • September 28, 2020
Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy

Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy

  • April 28, 2020
Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy

Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy

  • January 23, 2020
Vertex's Kalydeco (ivacaftor) Receives EC's Approval for Infants with Cystic Fibrosis with CFTR Gene Mutation Aged 6 to

Vertex's Kalydeco (ivacaftor) Receives EC's Approval for Infants with Cystic Fibrosis with CFTR Gene Mutation Aged 6 to

  • December 11, 2019
Vertex's Kalydeco (ivacaftor) Receives FDA's Approval for Cystic Fibrosis in Eligible Infants Aged 6 to Less than 12 Months

Vertex's Kalydeco (ivacaftor) Receives FDA's Approval for Cystic Fibrosis in Eligible Infants Aged 6 to Less than 12 Months

  • May 1, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.